Fulcrum Therapeutics (NASDAQ:FULC) Issues Earnings Results

Fulcrum Therapeutics (NASDAQ:FULC) released its earnings results on Tuesday. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.03), Zacks reports.

Fulcrum Therapeutics Stock Performance

Fulcrum Therapeutics stock opened at $3.70 on Tuesday. The stock has a market cap of $199.57 million, a PE ratio of -11.94 and a beta of 2.03. The stock has a fifty day moving average of $4.17 and a 200 day moving average of $4.66. Fulcrum Therapeutics has a one year low of $2.86 and a one year high of $13.70.

Analyst Upgrades and Downgrades

FULC has been the topic of a number of analyst reports. HC Wainwright reiterated a “neutral” rating and issued a $4.00 price target on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a report on Thursday, November 14th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $9.33.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.